Northland Securities Reiterates Buy Rating for Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by investment analysts at Northland Securities in a report released on Friday. They currently have a $72.00 target price on the biopharmaceutical company’s stock. Northland Securities’ target price would indicate a potential upside of 48.36% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on ESPR. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Stifel Nicolaus restated a “buy” rating and issued a $70.00 price objective (up previously from $60.00) on shares of Esperion Therapeutics in a report on Thursday, August 10th. Bank of America Corporation restated a “neutral” rating and issued a $60.00 price objective on shares of Esperion Therapeutics in a report on Friday, August 11th. Finally, Jefferies Group LLC upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and cut their price target for the company from $85.00 to $55.00 in a report on Tuesday, August 8th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Esperion Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $58.92.

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up $0.13 on Friday, reaching $48.53. 218,900 shares of the company’s stock were exchanged, compared to its average volume of 518,089. Esperion Therapeutics has a twelve month low of $10.30 and a twelve month high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same period last year, the firm posted ($0.77) EPS. equities analysts expect that Esperion Therapeutics will post -7.21 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Northland Securities Reiterates Buy Rating for Esperion Therapeutics, Inc. (ESPR)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/13/northland-securities-reiterates-buy-rating-for-esperion-therapeutics-inc-espr.html.

Hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN raised its position in Esperion Therapeutics by 25.1% in the third quarter. Wells Fargo & Company MN now owns 14,519 shares of the biopharmaceutical company’s stock worth $728,000 after acquiring an additional 2,917 shares during the period. Trexquant Investment LP bought a new position in Esperion Therapeutics in the third quarter worth approximately $832,000. Amundi Pioneer Asset Management Inc. bought a new position in Esperion Therapeutics in the third quarter worth approximately $9,517,000. American International Group Inc. raised its position in Esperion Therapeutics by 21.6% in the third quarter. American International Group Inc. now owns 11,257 shares of the biopharmaceutical company’s stock worth $564,000 after acquiring an additional 2,001 shares during the period. Finally, MUFG Securities EMEA plc bought a new position in Esperion Therapeutics in the third quarter worth approximately $9,022,000. Institutional investors own 90.05% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply